Phase 1 clinical study of TNB-409
Latest Information Update: 07 Sep 2022
Price :
$35 *
At a glance
- Drugs TNB-409 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 25 May 2021 New trial record
- 19 May 2021 According to a Teneobios media release, the company expect to initiate this trial in Q2 2022.